All In Biotech

Drug Trial Radar · NCT04243499

First-in-Human Study of ICT01 in Patients With Advanced Cancer

A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 293 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

293

Actual

Start

Mar 5, 2020

Primary completion

Oct 15, 2027

Study completion Oct 15, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 3 solid tumor indications for the combination of ICT01 plus pembrolizumab.

Conditions

  • Solid Tumor, Adult
  • Hematopoietic/Lymphoid Cancer

Interventions

  • IV ICT01Biological

    humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with TEAES (Part 1)Time frame: From baseline to at least 6 months
  2. Percentage of participants with TEAES leading to discontinuation of study treatment or treatment modifications (Part 1)Time frame: From baseline to at least 6 months
  3. Percentage of participants with SAEs (Part 1)Time frame: From baseline to at least 6 months
  4. Percentage of participants with clinically significant change from baseline clinical laboratory abnormalities (Part 1)Time frame: From baseline to at least 6 months
  5. Percentage of participants with clinically significant change from baseline vital sign readings (Part 1)Time frame: From baseline to at least 6 months
  6. Percentage of participants with clinically significant change from baseline in 12-lead Electrocardiogram (ECG) readings (Part 1)Time frame: From baseline to at least 6 months
  7. Percentage of participants with clinically significant change from baseline physical examinations (Part 1)Time frame: From baseline to at least 6 months
  8. Duration of Complete Response (DCR) (Part 2)Time frame: From baseline to at least 6 months

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Yale Cancer Center

    New Haven, Connecticut

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Montefiore Medical Center

    The Bronx, New York

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • US Oncology Research

    Irving, Texas

  • University of Washington

    Seattle, Washington

  • Institut Jules Bordet

    Brussels, Belgium

  • Institut Bergonie

    Bordeaux, France

  • Haut Leveque

    Bordeaux, France

  • Centre Hospitalier Lyon Sud

    Lyon, France

  • Centre Lyon Berard

    Lyon, France

  • CHU Lyon

    Lyon, France

  • Institut Paoli-Calmettes

    Marseille, France

  • CHU Nantes

    Nantes, France

  • Centre Antoine Lacassagne

    Nice, France

  • Pitie-Salpetriere

    Paris, France

  • Institut Curie

    Paris, France

  • Gustave Roussy

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • University Carl Gustav Carus Clinical Trial Unit

    Dresden, Germany

  • universitatklinikum Wurburg

    Würzburg, Germany

  • START Barcelone HM Nou Delfos

    Barcelona, Spain

  • Vall d'Hebron Instiute of Oncology

    Barcelona, Spain

  • START Madrid-FJD, Hospital Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Institute of Cancer Research

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.